PET scan study for chest pain in hypertrophic cardiomyopathy
Part of Heart & circulation clinical trials.
This trial uses a special PET scan to see if the drug Mavacamten (Camzyos) helps improve blood flow to the heart muscle in people with hypertrophic obstructive cardiomyopathy (HOCM) who have chest pain or shortness of breath. If you already take Mavacamten as part of your usual care, the study will compare your PET scan results before and after treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a confirmed diagnosis of hypertrophic obstructive cardiomyopathy (HOCM) with thickening of the heart wall.
- You have symptoms like chest pain or shortness of breath when active, and your doctor has ordered a special heart PET scan (called Rb-PET) to check for low blood flow (ischemia).
- You are eligible to take the drug Mavacamten (Camzyos) as part of your regular medical care.
- You have had a heart PET scan in the last 18 months that showed an abnormal result, or you are being scheduled for one now.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how heart medications affect blood flow in people with obstructive hypertrophic cardiomyopathy. You will have a heart MRI before and after starting or adjusting treatment to see how your heart responds.
This study looks at how mavacamten (a heart medication) works for people with obstructive hypertrophic cardiomyopathy (HCM)—a condition where heart muscle becomes too thick. Researchers will review medical records and ask patients about their experiences with the treatment.
This study tests whether the drug mavacamten (Camzyos) improves blood flow in the heart's small vessels for people with obstructive hypertrophic cardiomyopathy. You will take mavacamten as prescribed and have a PET/CT scan to measure your heart's blood flow reserve.
This trial tests whether a drug called mavacamten can help people with a specific type of thickened heart muscle (obstructive hypertrophic cardiomyopathy, or oHCM) by improving how the heart uses energy. It aims to understand if this treatment can improve symptoms and function.
This trial tests if mavacamten can help people with hypertrophic cardiomyopathy (HCM) who have obstruction in the middle or tip of the heart (not the usual outflow tract). You may join if you have symptoms like chest pain or shortness of breath and a pressure gradient above 30 mmHg in these areas.
This study tracks how people with obstructive hypertrophic cardiomyopathy feel and function while taking Camzyos (mavacamten). It aims to understand the real-world effects of the medication beyond clinical trials.
Hear when a new Hypertrophic Obstructive Cardiomyopathy \(HOCM\) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.